Some arthritis drugs may reduce Alzheimer’s and related dementias risk in those with heart disease

News Release

Advertisement

Friday, April 8, 2022

What

New findings from the ongoing Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study suggest that certain rheumatoid arthritis drugs may lower the incidence of Alzheimer’s disease and related dementias in people with cardiovascular disease. While the findings do not support the broad use of these drugs for treating Alzheimer’s and related dementias, the results may point to a promising precision-medicine approach in specific groups of people at risk for developing these diseases. The research was published in JAMA Network Open and led by Scientists at the National Institutes of Health’s National Institute on Aging in Collaboration with researchers at Harvard Medical School, Boston; Rutgers University, New Brunswick, New Jersey; and Johns Hopkins University School of Medicine, Baltimore.

Discovering new drug targets in Alzheimer’s and related dementias is crucial for meeting the enormous public health challenge of these diseases. Prior studies on whether approved rheumatoid arthritis drugs lower the risk of developing dementia have produced mixed results. In this study, researchers analyzed data in Medicare claims from more than 22,000 people, looking at whether those with rheumatoid arthritis who took one of three different classes of arthritis drugs were protected from dementia. There were no statistically significant associations with lowered dementia risk except among those with cardiovascular disease who were treated with one class of arthritis drugs called TNF inhibitors. These inhibitors suppress the immune system by blocking the activity of TNF, which is a substance in the body that can cause inflammation and lead to immune system diseases, including rheumatoid arthritis.

The NIA DREAM study previously identified several U.S. Food and Drug Administration-approved drugs that are being tested as candidate treatments for Alzheimer’s and related dementias.

Who

NIA experts are available for interviews to discuss specific findings of this paper and / or the broad view of the state of Alzheimer’s and related dementia research. NIA is the lead U.S. federal agency for research on these diseases. NIA Scientists and funded research teams are exploring drugs aimed at multiple different disease pathways, considering combinations of treatments, and working to repurpose existing drugs to treat Alzheimer’s and related dementias.

Study Senior Author:

  • Madhav Thambisetty, MD, Ph.D., Chief, Clinical and Translational Neuroscience Section, NIA Intramural Research Program

Broader Perspectives:

  • Richard J. Hodes, MD, NIA Director
  • Luigi Ferrucci, MD, NIA Scientific Director

The research was funded in part by the NIA Intramural Research Program project 1ZIAAG000436-01.

NIA leads NIH’s systematic planning, development, and implementation of research milestones to achieve the goal of effectively treating and preventing Alzheimer’s and related dementias. These activities relate to NIA’s AD + ADRD Milestone 7.B, “Initiate research programs for Translational Bioinformatics and network Pharmacology to support Rational drug repositioning and combination therapy from Discovery through clinical development.”

Reference

Desai R, et al. Comparative Risk Of Alzheimer’s Disease And Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Diseases-Modifying Antirheumatic Agents. JAMA Open. doi: 10.1001 / jamanetworkopen.2022.6567.

About the National Institute on Aging (NIA): NIA leads the US federal government’s effort to conduct and support research on aging and the health and well-being of older people. Learn more about age-related Cognitive change and neurodegenerative diseases via NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center website. Visit the main NIA website for information on a range of aging topics, in English and Spanish, and stay connected.

About the National Institutes of Health (NIH):The NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. The NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH… Turning Discovery Into Health®

###

.

Advertisement

What do you think?

Advertisement

Covid-19 Raises Risk of Lingering and Serious Blood Clotting, Swedish Study Finds

AI predicts if and when someone will experience cardiac arrest